Abstract
To investigate the influence of sialic acid removal on MUC1 peptidic and carbohydrate epitope reactivity in head and neck squamous cell carcinoma (HNSCC), tumor samples belonging to 24 HNSCC patients were studied by standard immunohisto-chemistry (IHC) with and without desialylation with 0.1 U/ml neuraminidase. From each tumor sample, subcellular fractions were obtained and analyzed by SDS-PAGE and Western blotting (WB). Three monoclonal antibodies (MAbs) were used: C595 MAb directed to MUC1 protein core, an anti-Tn hapten MAb, and an anti-sTn hapten MAb; a comparative analysis between desialylated and sialylated samples was performed. By IHC without neuraminidase treatment, 19 of 24 samples reacted with anti-MUC1 peptidic epitope, while Tn hapten was not detected and sTn was found in 1 of 24 cases. Desialylation increased either the number of reacting cells or the intensity of the reaction with C595 and anti-Tn MAbs, and some negative samples became positive. On the other hand, sTn expression decreased with desialylation. By WB, several bands from >200 to 25 kDa were found; desialylation increased high-molecular-weight bands, diminishing the detection of low-molecular-weight ones. The use of desialylation is a suitable treatment that contributes to the exposure of MUC1-associated epitopes, which may be related to the spreading of HNSCC.
Article PDF
Similar content being viewed by others
References
Bramwell ME, Wiseman G, Shotton DM: Electron-microscopic studies of the CA antigen, epitectin. J Cell Sci 86:249–261, 1986.
Brockhausen I, Yang J-M, Burchell J et al: Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. Eur J Biochem 223:607–617, 1995.
Bryne M, Gravdahi C, Koppang HS et al: Is the carbohydrate sialosyl-Tn a marker for altered, non-malignant activity in squamous epithelium in the head and neck region? J Pathol 175:237–242, 1995
Burchell J andTaylor-Papadimitriou J: Effect of modification of carbohydrate side chains on the reactivity of antibodies with core-protein epitopes of the MUC1 gene product. Epithelial Cell Biol 2:115–162, 1993.
Ciborowski P, Konitzi WM, Magarian Blander J, et al: Screening of anti-MUC1 antibodies for reactivity with native (ascites) and recombinant (Baculovirus) MUC1 and for blocking MUC1 specific cytotoxic T-lymphocytes. Tumor Biol 19 (Suppl 1):147–151, 1998.
Croce MV, Colussi A, Price MR, et al: Expression of tumor associated antigens in normal, benign and malignant human mammary epithelial tissue: a comparative study. Anticancer Res 17:4287–4292, 1997.
Croce MV, Rabassa ME, Price MR, et al: MUC1 mucin and carbohydrate associated antigens as tumor markers in head and neck squamous cell carcinoma. Pathol Oncol Res 7:284–291, 2001.
Croce MV, Isla-Larrain M, Rua C, et al: Patterns of MUC1 cytoplasmic tail monoclonal antibody in breast cancer. J Histochem Cytochem 5:1–8, 2003.
Dabelsteen E, Clausen H, Mandel U: Aberrant glycosylation in oral malignant and premalignant lesions. J Oral Path Med 20:361–368, 1991.
Dalziel M, Whitehouse C, Mcfarlane I, et al: The relative of the C2Gn T1 and ST3Gal-I glycosyltransferases determine O-glycan structure and expression of a tumor-associated epitope on MUC1. J Biol Chem 276:11007–11015, 2001.
Farmer RW, Richtsmeier WJ, Scher RL: Identification of sialyl Lewis-x in squamous cell carcinoma of the head and neck. Head Neck 20:726–731, 1998.
Feickert HJ, Anger BR, Cordón-Cardo C, et al: Cell-surface antigens of human tumors detected by mouse monoclonal antibodies: definition of blood-group- and non-blood-group-related antigenic systems. Int J Cancer 46:1007–1013, 1990.
Gendler SJ, Taylor-Papadimitriou J, Duhig T: A highly immunogenic region of human polymorphic mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 263:12820–12823, 1988.
Gendler S: MUC1, the renaissance molecule. J Mamm Gland Biol Neoplasia 6:339–353, 2001.
Gleich LL, Ryzenman J, Gluckman JL et al: Recurrent advanced (T3 or T4) head and neck squamous cell carcinoma: is salvage possible? Arch Otolaryngol Head Neck Surg 130:35–38, 2004.
Hakomori S-I: Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res 52:257–331, 1989.
Ho JJL, Cheng S, Kim YS: Access to peptide regions of a surface mucin (MUC1) is reduced by sialic acids. Biochem Biophys Res Commun 210:866–873, 1995.
Irimura T, Denda K, Iida S, et al: Diverse glycosylation of MUC1 and MUC2: potential significance in tumor immunity J Biochem 126:975–985, 1999.
Itoh T, Yonezawa S, Nomoto M, et al: Expression of mucin antigens and Lewis X-related antigens in carcinomas and dysplasia of the pharynx and larynx. Pathol Int 46:646–655, 1996.
Itzkowitz SH, Bloom EJ, Kokal WA, et al: Sialosyl Tn: a novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 66:1960–1966, 1990.
Jeannon J-P, Stafford FW, Soames JV, et al: Altered MUC1 and MUC2 glycoprotein expression in laryngeal carcinoma. Otolaryngol Head Neck 124: 199–202, 2000.
Kam JL, Regimbald LH, Hilgers JH, et al: MUC1 synthetic peptide inhibition of intercellular adhesion molecule-1 and MUC1 binding requires six tandem repeats. Cancer Res 58: 5577–5581, 1998.
Kjeldsen T, Clausen H, Hirohashi S, et al: Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2-6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope. Cancer Res 48:2214–20, 1988.
Kunz H: Synthetic glycopeptides for the development of tumor-selective vaccines. J Pept Sci 9: 563–573, 2003.
Kurahara S, Shinohara M, Ikebe T, et al: Immunohistochemical study of sialyl Le(a) and sialyl Le(x) antigen in oral squamous cell carcinoma: the association of sialyl Le(a) expression with the metastatic potential. Head Neck 21:330–337, 1999.
Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685, 1970.
Lloyd KL, Burchell J, Kudryashov V, et al: Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells. J Biol Chem 271:33325–33334, 1996.
Luna-Moré S, Rius F, Weil B, et al: EMA: a differentiation antigen related to node metastatic capacity of breast carcinomas. Pathol Res Pract 197:419–425, 2001.
Mandel U, Petersen OW, Sorensen H, et al: Simple mucin-type carbohydrates in oral stratified squamous and salivary gland epithelia. J Invest Dermatol 97:713–721, 1991.
Müller S andHanisch F-G: Recombinant MUC1 probe authentically reflects cell-specific O-glycosylation profiles of endogenous breast cancer mucin. J Biol Chem 277:26103–26112, 2002.
Musselli C, Livingston PO, Ragupathi G: Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience. J Cancer Res Clin Oncol 127 (Suppl 2):R20–26, 2001.
Ogawa H, Ghazizadeh M, Araki T: Tn and sialyl-Tn antigens as potential prognostic markers in human ovarian carcinoma. Gynecol Obstet Invest 41:278–283, 1996.
Price MR, Pugh JA, Hudecz F, et al: C595 — a monoclonal antibody against the protein core of human urinary epithelial mucin commonly expressed in breast carcinomas. Br J Cancer 61: 681–686, 1990.
Regimbald LH, Pilarski LM, Longenecker BM: The breast mucin MUC1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res 56:4244–4249, 1996.
Renkonen J, Paavonen T, Renkonen R: Endothelial and epithelial expression of sialyl Lewis x and sialyl Lewis a in lesions of breast carcinoma. Int J Cancer 74:296–300, 1997.
Rubin JS, Bloor BK, Hart IR, et al: muc-1 gene expression in head and neck squamous cell carcinoma. J Laryngol Otol 114:772–776, 2000.
Shi SR, Cote RJ, Taylor CR: Antigen retrieval techniques: current perspectives. Histochem Cytochem 49:931–937, 2001.
Spencer DI, Price MR, Tendler SJ, et al: Effect of glycosylation of a synthetic MUC1 mucin-core-related peptide on recognition by anti-mucin antibodies. Cancer Lett 100:11–15, 1996.
Stenersen TC, Dabelsteen E: Changes in the glycosylation pattern of histo-blood group antigens in benign, premalignant and malignant laryngeal epithelial lesions. APMIS 27(Suppl):139–148, 1992.
Taylor-Papadimitriou J, Burchell J, Miles DW, et al: MUC1 and cancer. Biochim Biophys Acta 1455:301–313, 1999.
Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76:4350–4354, 1979.
Wesseling J, van der Van SW, Vos HL, et al: Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 129:255–265, 1995.
Zhang S, Walberg LA, Ogata S, et al: Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen. Cancer Res 55:3364–3368, 1995.
Zhang K, Baeckstrom D, Brevinge H, Hanasson GC: Secreted MUC1 mucins lacking their cytoplasmic part and carrying sialyl-Lewis a and x epitopes from a tumor cell line and sera of colon carcinoma patients can inhibit HL-60 leukocyte adhesion to E-selectin-expressing endothelial cells. J Cell Biochem 60:538–549, 1996.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Croce, M.V., Rabassa, M.E., Pereyra, A. et al. Influence of sialic acid removal on MUC1 antigenic reactivity in head and neck carcinoma. Pathol. Oncol. Res. 11, 74–81 (2005). https://doi.org/10.1007/BF02893370
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02893370